Course Outline
Click on the links below to preview selected pages from this course.
- Case Scenario
- Initial Serologic Test Results
- ABO/Rh Typing and Antibody Screen
- Which of the following are possible causes of the positive antibody screen?
- Why might screen cell #2 be reacting stronger than screen cell #1?
- Antigram
- Which of the possible causes is the most likely cause of the positive antibody screen?
- Perinatal Testing Programs
- Interpreting Initial Serologic Tests
- Interpreting Initial Serologic Tests
- Antibody Exclusion Protocol (General)
- Initial Antibody Exclusions
- Antibody Exclusion Protocols (RhIG)
- Passive or Active Immunization?
- RhIG-Derived Anti-D Reaction Strength
- Factors Affecting RhIG Reaction Strength
- How Long Can RhIG Be Detected?
- Which of the following factors is most likely to cause a false-negative antibody screen following RhIG injection?
- True or False: A pregnant patient has been injected with RhIG antenatally and has a positive antibody screen at delivery. If the antibody has been con...
- True or False: A pregnant patient who received RhIG at 28 weeks gestation has a positive antibody screen at delivery. If the antibody has been confirm...
- Follow-up Serologic Tests
- How Much Testing?
- Mini-Panel Antibody Exclusion
- True or False: Using the guidelines in the antibody exclusion protocol, all unexcluded antibodies (anti-C, E, K, Fyb, Jka, N, s) have been excluded by...
- Post-Delivery Testing
- Serologic Tests on Newborn
- True or False: The newborn's ABO group is invalid because no reverse (serum) group was set up with A1 and B cells.
- True or False: The newborn's Rh(D) type is invalid because the DAT is positive.
- True or False: The positive DAT on the newborn means that the infant probably has clinically significant hemolysis.
- Newborn's Clinical Status
- Is the mother a candidate for RhIG?
- Screening for Fetomaternal Hemorrhage (FMH)
- Quantifying FMH
- Kleihauer-Betke (KB) Test
- Flow Cytometry
- Calculating RhIG Dosage
- Assessing FMH and RhIG Dosage
- Which of the following tests are suitable for quantifying the size of fetomaternal hemorrhage (FMH)?
- True or False: Facilities that use a special calculation for RhIG dosage add one vial, regardless of whether they round up or round down.
- Summary and Conclusions
- When Transfusion Is Necessary
- Crossmatch Issues
- Crossmatch Implications of RhIG-Associated Passive Anti-D
- Introduction to Crossmatch Practices Related to RhIG
- LIS Issues Related to RhIG
- Examples of Crossmatch Practices Related to RhIG
- True or False: Blood safety standards, such as AABB Standards, directly specify that an electronic crossmatch cannot be done when an Rh-negative mothe...
- References
Additional Information
Level of Instruction: Intermediate
Intended Audience: Medical laboratory scientists, medical laboratory technicians, laboratory supervisors, and laboratory managers. This course is also appropriate for MLS and MLT students and pathology residents.
Author Information: Pat Letendre, MEd is a laboratory technologist, educator, and consultant. Currently, she consults full-time in the areas of transfusion medicine, education, and professional development. Ms. Letendre is the Webmaster for Canada's transfusion safety officers and the TraQ website coordinator. She holds a Master of Education degree in adult education from the University of Alberta and a Bachelor of Science degree from the University of Manitoba.
The author has no conflict of interest to disclose.
Reviewer Information:
Joshua J. Cannon, MS, MLS(ASCP)CMSHCM received his Bachelor of Science and Master of Science in Medical Laboratory Science from Thomas Jefferson University in Philadelphia, PA. He holds Medical Laboratory Scientist and Specialist in Hematology certifications through the ASCP Board of Certification. He was a professor at Thomas Jefferson University for seven years before transitioning into his current role as Education Developer at MediaLab by Vastian. His areas of expertise and professional passions include clinical hematology and interprofessional education.
Laurie Bjerklie, MA, MLS(ASCP)CM is a Lead Education Developer. She earned a B.S. in Medical Laboratory Science from the University of North Dakota and an M.A. in Curriculum and Instruction from Saint Xavier University. She has over 15 years of experience in higher education and has held program director and faculty positions in both MLT and MLS programs.
